<DOC>
	<DOC>NCT00162695</DOC>
	<brief_summary>Objective of the study objectives was to explore survival advantage for an intensified chemotherapy strategy in a randomised trial. IVA (ifosfamide, vincristine, actinomycin D) or a 6 drug combination (IVA + carboplatin, epirubicin, etoposide) both delivered over 27 weeks. Cumulative dose / m2 = ifosfamide 54g (both arms), epirubicin 450 mg, etoposide 1350 mg (6 drug). Delivery of radiotherapy was determined according to site and / or response to chemotherapy Â± surgery. The study was powered to detect 10% difference in 3 year OS.</brief_summary>
	<brief_title>Rhabdomyosarcoma and Malignant Soft Tissue Tumours of Childhood</brief_title>
	<detailed_description />
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>age &gt; 6 months and &lt; 18 years no distant metastases diagnosis within previous 8 weeks without prior treatment except surgery pathology available for central review written consent according to institutional requirement stage III (node positive) stage I or II non alveolar orbital tumours patients with parameningeal disease aged &lt; 3 years</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>